Barbara A. Murphy, MD

Articles by Barbara A. Murphy, MD

Topoisomerase I Inhibitors in the Treatment of Head and Neck Cancer

ByBarbara A. Murphy, MD,Anthony J. Cmelak, MD,Brian Burkey, MD,James Netterville, MD,Yu Shyr, PhD,Stacey Douglas, RN

July 1st 2001

Traditionally, the role of chemotherapy in the treatment ofsquamous carcinoma of the head and neck has been confined to patients with

Combined-Modality Therapy for Locoregionally Advanced Head and Neck Cancer

ByAnthony J. Cmelak, MD,Barbara A. Murphy, MD,Terry Day, MD

October 1st 1999

Traditionally, treatment for locally advanced resectable head and neck cancer has been surgical resection followed by postoperative radiation. In unresectable patients, primary radiation has been the mainstay of

Latest Updated Articles

Combined-Modality Therapy for Locoregionally Advanced Head and Neck Cancer
October 1st 1999
Topoisomerase I Inhibitors in the Treatment of Head and Neck Cancer
July 1st 2001

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Achieving a “Functional Cure” With Multiple Myeloma Therapy

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)